88
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Extranodal NK/T-Cell Lymphoma Occurring Primarily in the Eyes and with Central Nervous System Relapse

ORCID Icon, , &
Pages 6579-6583 | Published online: 20 Aug 2021

References

  • ChanJKC, Quintanilla-MartinezL, FerryJA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: SwerdlowSH, CampoE, HarrisNL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017:368–371.
  • AuWY, WeisenburgerDD, IntragumtornchaiT, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113:3931–3937. doi:10.1182/blood-2008-10-18525619029440
  • KimSJ, YoonDH, JaccardA, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389–400.26873565
  • ReddyEK, BhatiaP, EvansRG. Primary orbital lymphomas. Int J Radiat Oncol Biol Phys. 1988;15:1239–1241. doi:10.1016/0360-3016(88)90210-63053542
  • SagooMS, MehtaH, SwampillaiAJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59:503–516. doi:10.1016/j.survophthal.2013.12.00124560125
  • HonC, KwokAK, ShekTW, et al. Vision-threatening complications of nasal T/NK lymphoma. Am J Ophthalmol. 2002;134:406–410. doi:10.1016/S0002-9394(02)01520-912208253
  • AbeRY, PintoRD, BonfittoJF, et al. Ocular masquerade syndrome associated with extranodal nasal natural killer/T-cell lymphoma: case report. Arq Bras Oftalmol. 2012;75:430–432. doi:10.1590/S0004-2749201200060001323715149
  • ZhangF, DuanX, LiuK. A case report of an extranodal NK/T-cell lymphoma nasal type, occurring primarily in eyes with masquerade syndrome. Medicine (Baltimore). 2019;98:e14836. doi:10.1097/MD.000000000001483630882672
  • YamaguchiM, KwongYL, KimWS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol. 2011;29:4410–4416. doi:10.1200/JCO.2011.35.628721990393
  • WangJH, LiangW, LiuCC, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget. 2016;7:29092–29101. doi:10.18632/oncotarget.864727093153
  • TomiM, HosoyaK. The role of blood-ocular barrier transporters in retinal drug disposition: an overview. Expert Opin Drug Metab Toxicol. 2010;6:1111–1124. doi:10.1517/17425255.2010.48640120438316
  • TangLJ, GuCL, ZhangP. Intraocular lymphoma. Int J Ophthalmol. 2017;10:1301–1307.28861359
  • ZhuangL, LaiJ, ChenK, et al. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. Oncol Rep. 2019;41:397–404.30320386
  • KimH, JeongH, YamaguchiM, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136(22):2548–2556. doi:10.1182/blood.202000502632584959